CLINICAL_TRIALS
trial_result
· 2025-08-06
Clinical Trial Update: Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)
Summary
A post-marketing surveillance study of empagliflozin (JARDIANCE) in chronic heart failure has been completed and its results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Heart Failure | Status: COMPLETED | Results posted: 2025-08-06